Articles tagged with Flu Vaccines
The National Institute of Allergy and Infectious Diseases has awarded contracts to nine institutions, including Group Health Research Institute, to expand vaccine and treatment evaluation units. These centers will conduct clinical trials for promising candidate vaccines and therapies, aiming to protect the public from infectious diseases.
Duke Medicine has been named a Vaccine and Treatment Evaluation Unit (VTEU) to evaluate vaccines, treatments, and diagnostics. The VTEU will focus on vaccine development for diseases other than HIV, with potential annual funding of up to $135 million.
Researchers have found no significant evidence of an increased risk of birth defects in babies born to mothers who received the H1N1 influenza vaccine during pregnancy. The study, which followed over 1,000 pregnant women across the US and Canada, also found that vaccinated women were more likely to deliver earlier, but only slightly so.
Researchers found no evidence of an increased risk for specific major birth defects in mothers who received the flu shot. However, there was a slight increase in preterm delivery rates among vaccinated women during certain seasons.
The National Institutes of Health (NIH) is funding new bird flu vaccine studies to protect against a deadly strain that caused severe disease in China last spring. The study aims to fine-tune the process of creating an effective vaccine, with the goal of preventing future pandemics.
Researchers at the University of Maryland are developing a vaccine to protect adults from the H7N9 influenza virus, which has caused 135 human cases and 44 deaths in China. The study aims to gather critical information on the safety and effectiveness of the vaccine and its ability to induce an immune response.
Researchers developed a microneedle patch that delivered an effective and long-lasting influenza vaccine, providing 100% protection in mice over one year. The vaccine used virus-like particles coated on needles, reducing refrigeration needs and potential side effects.
A McMaster study found that new mothers and obese individuals are more susceptible to severe influenza outcomes, despite not being considered high-risk groups. The research highlights the need for precise definition of risk factors to optimize vaccine allocation during epidemics.
Researchers at The Wistar Institute found that sequential vaccination with distinct influenza strains can stimulate immune responses against multiple strains. This approach offers an alternative to creating a universal flu vaccine by targeting conserved regions of the virus, potentially providing long-term immunity.
Older African-American and Hispanic male cancer survivors are more likely to miss specialist visits and preventive care, such as vaccinations, compared to their white counterparts. The study found that disparities persist despite access to Medicare and adjustments for factors like education and insurance.
A new study by St. Michael's Hospital found that the flu shot is effective in preventing the flu, even if the virus going around does not match the vaccine. The review of over 40 years of data showed significant protection against both matched and mismatched flu strains.
A 13-year Kaiser Permanente study found no association between vaccination and increased risk of Guillain-Barré syndrome. Researchers controlled for seasonality and analyzed 415 cases, finding only 25 patients had received a vaccine in the six weeks prior to illness onset.
According to a study published in PLOS ONE, the flu vaccine likely prevented approximately 13 million illnesses and over 110,000 hospitalizations in the US between 2006 and 2011. The researchers estimated this impact based on vaccination coverage and vaccine effectiveness.
A new report suggests that vaccinating more children and young adults for influenza could significantly reduce the number of lives lost and economic burden associated with seasonal influenza. The study's findings suggest that programs targeting these age groups would have the best payoff in breaking the annual transmission cycle.
A four-year analysis of Loyola University Health System's mandatory flu vaccination policy shows that workers do not quit due to the requirement. The policy led to a 99 percent compliance rate and enhanced patient safety.
A four-year analysis found that mandatory influenza vaccination in a university medical center led to a near-universal vaccination rate, with fewer than 15 employees out of 8,000 choosing termination over vaccination. The policy also enhanced patient and staff safety, resulting in improved outcomes.
Two studies identify specific HA mutations in H5N1 and H7N9 viruses that enhance infectivity in the human respiratory tract. These findings can inform monitoring and vaccine development for emerging bird flu strains.
A new study found that school-located vaccination clinics increased flu vaccination rates among children by 13.2 percentage points, despite higher initial costs. The program may be a cost-effective way to broaden access to flu vaccines for children, particularly in primary-care settings.
Researchers develop a gene therapy that gives mice complete protection against lethal strains of H5N1 and H1N1 flu virus, including the infamous 1918 flu. The treatment involves expressing a broadly neutralizing antibody in nasal epithelial cells, providing substantial reductions in flu replication and virus load.
A novel vaccine concept using HA-ferritin nanoparticles elicited a potent immune response and broad protection against H1N1 virus strains. The experimental vaccine was also active against a wider range of strains than the licensed seasonal influenza vaccine.
Researchers have developed a novel vaccine delivery system that mimics pathogens to stimulate the immune system without causing infection. The technology uses inulin acetate from plant fibers, showing promise for preventing viral diseases such as influenza, with an estimated cost of one or two dollars per dose.
A*STAR and Cytos have initiated a Phase 1 clinical trial for Singapore's first H1N1 influenza vaccine candidate based on Cytos' proprietary bacteriophage Qbeta virus-like particle (VLP) technology. The vaccine aims to provide an effective means of combating influenza epidemics and pandemics in Singapore and the ASEAN region.
A Johns Hopkins fellow argues that the US public health agency's message on influenza vaccines may be overstated, with limited evidence supporting the claim that vaccines save lives. He also questions the effectiveness of vaccines in reducing elderly deaths and highlights potential side effects.
The H5N1 vaccine candidate induced a solid immune response in all three configurations of adjuvant and route of administration, exceeding the CHMP immunogenicity criteria. The results demonstrate the potential for significant 'dose-sparing' with the intradermal delivery device.
IDRI and Medicago present data on their H5N1 Avian Influenza VLP vaccine candidate, combining IDRI's GLA adjuvant with Medicago's proprietary manufacturing technology. The trial shows promising results in evaluating the safety and immunogenicity of the vaccine.
Researchers at UBC and Israel discovered that compliant physicians lead to more patient adherence to screening and vaccination practices. The study found significant differences in patients of doctors who received flu shots and those who did not, highlighting the importance of healthcare professionals' health habits on their patients.
A study published in Canadian Medical Association Journal found that physicians who followed recommended screening and vaccination practices had more likely patients to also follow these practices. The research involved 1488 physicians and their adult patients in Israel's largest health maintenance organization, Clalit Health Services.
A study by Penn State University researchers found that exposure to negative sentiment on Twitter is contagious, while positive sentiments are not. Microbloggers with reciprocal relationships tend to be influenced differently depending on the vaccine sentiments of their connections, with negative sentiments being more socially contagious.
A 14-year study found the varicella vaccine to be approximately 90% effective in preventing chicken pox, with a significant decrease in breakthrough cases over time. The second dose of varicella vaccine was found to be unnecessary for prevention of moderate to severe disease.
A new vaccine has proven highly effective against the H5N1 avian influenza virus, when tested in mice and ferrets. The vaccine uses an attenuated version of the H9 virus with an added H5 gene, slowing viral replication and reducing the risk of successful reassortment.
Researchers identified a unique subset of helper T cells that stimulates protective antibody responses following seasonal influenza vaccinations. The study found that these T cells boost production of existing antibodies by stimulating memory B cells, but do not help produce new antibodies by naïve B cells.
A meta-analysis found a small excess risk of Guillain-Barré syndrome associated with H1N1 flu vaccination. However, the benefits of vaccination significantly outweighed the risks. The study analyzed data from 23 million people vaccinated in the USA during the 2009 pandemic.
A study found a 14-fold increased risk of narcolepsy after receiving the AS03 adjuvanted pandemic A/H1N1 2009 vaccine, with vaccination within six months associated with an even higher risk. The authors suggest that the true risk may be lower due to delayed diagnosis.
A UCLA study found a link between untreated depression and decreased effectiveness of the shingles vaccine in older adults. Patients with depression showed a weaker immune response to the varicella-zoster virus, making them less responsive to the vaccine.
The ACIP has updated its recommended 2013 adult immunization schedule to include new guidelines for the use of pneumococcal conjugate and influenza vaccines. The updated schedule also recommends routine Tdap vaccination for adults aged 65 or older, pregnant women, and all patients over 6 months old against influenza.
A study published in the New England Journal of Medicine found that H1N1 flu shots do not increase the risk of pregnancy loss. In fact, vaccination reduces the risk of fetal loss by up to twofold compared to influenza infection alone.
A new study found that less than 45% of children were vaccinated against the flu during a five-year period, highlighting the need for increased vaccination efforts. The study also revealed that children under 6 months old had the highest hospitalization rates with flu, emphasizing the importance of protecting infants through vaccination.
Researchers led by Dr. Robert W. Finberg are working on a $12 million project to improve flu vaccine effectiveness by predicting the influenza virus's evolution in response to anti-viral drugs and human immune systems. The approach could potentially boost protection rates, reducing severe illness cases.
Researchers estimate naloxone distribution could prevent 6.5% of all overdose deaths by providing a cost-effective way to reverse opioid overdoses. Quadruple doses of seasonal flu vaccine may better protect HIV-infected patients from serious illness or death, but evidence for quality impact is limited.
Researchers at Georgia State University have developed a new process for creating a one-time, universal influenza vaccine using recombinant genetic engineering technology. This breakthrough aims to prevent the need for annual updates and shortages of flu vaccines.
According to a study by Wake Forest Baptist Medical Center, only one in five college students received the flu vaccine during the 2009-2010 season. The researchers suggest that colleges implement new or improved influenza vaccine strategies, such as giving flu shots at sporting events, to increase vaccination rates.
Researchers developed a microneedle technique to dry and stabilize the measles vaccine, showing it remained effective for at least 30 days. The method could provide a new tool for international immunization programs against measles, which killed nearly 140,000 children in 2010.
In an editorial published in CMAJ, Dr. Ken Flegel argues that a mandatory flu vaccine for healthcare workers is necessary due to the high risk of transmission and severe illness. With 55% of physicians not getting vaccinated, hospitals are at risk of outbreaks, emphasizing the need for compulsory vaccination rates above 90%.
The influenza vaccine has been shown to reduce the risk of major cardiac events such as strokes, heart attacks, and cardiac deaths by approximately 50 percent. A similar trend was seen for reducing death from any cause, with a reduction of around 40 percent.
Pediatric studies show that influenza can be fatal even in healthy children, with 43% of deaths occurring in those without underlying health conditions. School-based vaccination programs are effective in protecting student populations and preventing community spread.
A large study of nearly 200,000 females who received the HPV4 vaccine found that immunization was associated with same-day syncope and skin infections after vaccination. The findings support the general safety of routine vaccination with HPV4 in preventing cervical and other genital cancers.
Researchers analyzed DNA sequences of thousands of influenza strains to predict trends and understand the rules of flu virus evolution. This knowledge can help develop more effective vaccines against emerging strains.
Researchers at Stanford University School of Medicine discovered that blocking the action of a specific protein called DUSP6 can restore an important class of immune cells' response to vaccines. This finding holds long-term therapeutic ramifications and could potentially counter aging's effects on the immune system.
A study found that protection against whooping cough decreases by more than 40% each year after the fifth dose of DTaP vaccine. The decline in protection depends on the initial effectiveness of the fifth dose, with lower effectiveness leading to reduced protection.
A new study found that flu vaccination rates vary widely by ethnicity in Canada, with non-white Canadians having lower rates. The study analyzed data from 12 ethnic groups and found significantly higher vaccination rates among Filipino, Japanese, and Chinese Canadians compared to white and black Canadians.
Researchers have identified how immature immune cells respond to the influenza virus and traced the path to generate antibodies that can neutralize a wide range of strains. This understanding could aid in designing a universal flu vaccine that provides protection against most or all influenza virus strains.
The trial aims to evaluate the safety and immunogenicity of the H5N1 vaccine combined with IDRI's GLA adjuvant, which may result in a self-administered flu vaccine. The collaboration has the potential to expedite vaccination and simplify distribution during a pandemic.
Visits to retail medical clinics increased four-fold from 2007 to 2009, with a significant increase in younger patients seeking convenient care. The proportion of visits for preventive care, including vaccinations, rose to over 47% by 2009.
Researchers found that a prime-boost vaccine regimen can elicit broadly neutralizing antibodies in animals with pre-existing immunity, offering hope for developing vaccines giving long-lasting flu protection. The study's results suggest that a universal flu vaccine may be possible, potentially benefiting people of all ages.
Researchers at Scripps Research Institute describe three human antibodies protecting against a wide variety of flu viruses, including Influenza B strains. These broadly neutralizing antibodies may provide key clues to designing an active universal flu vaccine.
Two studies found that infants exposed to the H1N1 vaccine in utero did not have a significantly increased risk of major birth defects, preterm birth, or fetal growth restriction. However, adults exposed to the vaccine were at a small increased risk of Guillain-Barre syndrome during the 4-8 weeks after vaccination.
A recent study found a small but significant risk of Guillain-Barre syndrome following H1N1 vaccination, primarily in individuals over 50 years old. The risk was estimated to be approximately 2 cases per 1 million doses, with most cases occurring within 4 weeks of vaccination.
A University of Louisville study reviewed medical literature to debunk fears about drive-thru flu clinics. The researchers found no evidence of fainting episodes or related auto accidents among over 50,000 vaccine recipients since the program's inception in 1995.
A successful swine flu vaccination program in Scotland showed 77% protection against the H1N1 virus, while also reducing hospital admissions by 20% due to related disorders. The program's effectiveness was demonstrated through detailed data analysis, which took into account multiple conditions such as pneumonia and COPD.
Researchers have made a significant discovery that the pandemic 2009 H1N1 vaccine can produce antibodies against not only the H1N1 virus but also other influenza virus strains including H5N1 and H3N2. This breakthrough brings the team closer to developing a pan-influenza vaccine that can reliably induce broadly cross-reactive antibodies.